Advertisement
BIIB or REGN or VRTX
Which Stock Would AI Choose? Biogen (BIIB) vs. Regeneron Pharmaceuticals (REGN) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- BIIB leads YTD performance at +5.06% and 1-year gains of +31.89%, driven by strong Q4 earnings and neurology pipeline momentum.
- REGN shows stability with YTD +3.16% and 1-year +12.96%, bolstered by positive Phase 3 obesity drug data.
- VRTX exhibits recent surge from kidney disease trial success, with YTD +5.75% but flat 1-year return amid CF franchise growth.
- BIIB trades at lowest P/E (~21) versus REGN (~50+) and VRTX (~30), suggesting relative value.
- All three benefit from robust pipelines in neurology, immunology, and rare diseases, with analyst targets implying upside: BIIB $206, REGN $875, VRTX $553.
Introduction
Biogen (BIIB), Regeneron Pharmaceuticals (REGN), and Vertex Pharmaceuticals (VRTX) represent leading biotech firms focused on neurology, immunology, and rare diseases. This stock comparison evaluates their recent performance, pipelines, and market positioning amid evolving sector dynamics like pipeline catalysts and earnings beats. Traders seeking momentum and investors eyeing long-term growth in biopharma will find insights into relative strengths, such as BIIB's value or VRTX's stability, helping inform decisions in a competitive healthcare landscape.
BIIB Overview and Recent Performance
Biogen (BIIB), a pioneer in multiple sclerosis therapies, focuses on neurology and rare diseases with products like Leqembi for Alzheimer's and Qalsody for ALS. In recent market activity, shares have gained over 10% in the past three months, outperforming the healthcare sector, with YTD returns at +5.06% and 1-year at +31.89%. Strong Q4 2025 earnings, featuring adjusted EPS of $1.99 beating estimates and newer products generating $1 billion annually, fueled sentiment. Positive data on salanersen for SMA and upbeat 2026 profit forecasts have supported momentum, though shares trade below 52-week highs amid broader MS pressures.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) specializes in monoclonal antibodies and genetic medicines, with blockbusters like Dupixent for eczema and Eylea for eye diseases. Recent weeks show mixed price action, with 90-day returns at +3.73% and 1-year at +12.96%, reflecting stability. Positive Phase 3 results for olatorepatide in obesity, demonstrating significant weight loss, have boosted pipeline optimism. Q4 profit beats from Dupixent demand and collaborations sustain performance, though competition in eye therapies tempers gains. Shares hover near $747, with YTD +3.16%.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals (VRTX) dominates cystic fibrosis treatments with Trikafta and advances gene therapies like Casgevy for sickle cell disease. Recent activity features an 8.3% surge from positive Phase 3 povetacicept data in IgA nephropathy, with 3-month gains at +7.51% and YTD +5.75%. Q4 2025 revenue hit $3.19 billion, up 10%, with 2026 guidance at $12.95-13.1 billion. CF franchise expansion and non-CF ramps drive sentiment, though 1-year returns lag at -3.49% amid high valuations.
Trending AI Robots
Tickeron's Trending AI Robots page curates over 25 top-performing AI trading bots from hundreds available, selected by AI for suitability in current market conditions like volatility. These bots trade thousands of tickers across stocks, ETFs, and crypto in sectors from semiconductors to aerospace, using diverse strategies—technical/fundamental analysis, trend following, hedging—with timeframes from 5 minutes to 62 days. Performance highlights include annualized returns of +17% to +216%, win rates up to 95%, and profit factors to 25.8, with low drawdowns and multi-ticker portfolios. Explore these adaptable tools tailored to prevailing trends and consider subscribing for automated insights.
Head-to-Head Comparison
BIIB, REGN, and VRTX share biotech exposure but diverge in models: BIIB's neurology focus contrasts REGN's immunology breadth and VRTX's CF/rare disease dominance. Growth drivers include BIIB's Leqembi ramp, REGN's obesity pipeline, and VRTX's gene editing. Recent momentum favors BIIB (1Y +32%) over VRTX (-3%). Risks: BIIB faces MS erosion, REGN eye competition, VRTX high P/E (~30). BIIB offers value (P/E 21, $27B cap), VRTX scale ($121B), REGN balance ($85B+). Sentiment tilts positive on catalysts.
Tickeron AI Verdict
Tickeron's AI currently favors BIIB for its trend consistency, relative valuation, and pipeline catalysts like SMA advances, positioning it strongly versus peers' higher multiples and mixed momentum. Probabilistic edge stems from earnings beats and undervaluation signals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s), and VRTX’s FA Score reflects 0 green FA rating(s).
- BIIB’s FA Score: 1 green, 4 red.
- REGN’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 2 bullish TA indicator(s), and VRTX’s TA Score reflects 4 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 5 bearish.
- REGN’s TA Score: 2 bullish, 6 bearish.
- VRTX’s TA Score: 4 bullish, 3 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +2.53% price change this week, while REGN (@Biotechnology) price change was +0.23% , and VRTX (@Biotechnology) price fluctuated +1.13% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
BIIB is expected to report earnings on Apr 29, 2026.
REGN is expected to report earnings on Apr 29, 2026.
VRTX is expected to report earnings on May 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BIIB | REGN | VRTX | |
| Capitalization | 26B | 79.4B | 112B |
| EBITDA | 2.6B | 5.82B | 4.87B |
| Gain YTD | 0.773 | -2.643 | -2.682 |
| P/E Ratio | 20.18 | 18.09 | 28.80 |
| Revenue | 9.89B | 14.3B | 12B |
| Total Cash | 3.82B | 8.61B | 6.61B |
| Total Debt | 6.58B | 2.71B | 2.03B |
BIIB | REGN | VRTX | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 60 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 3 Undervalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 75 | 35 | |
SMR RATING 1..100 | 78 | 54 | 40 | |
PRICE GROWTH RATING 1..100 | 47 | 47 | 60 | |
P/E GROWTH RATING 1..100 | 14 | 40 | 53 | |
SEASONALITY SCORE 1..100 | 90 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for VRTX (80) and is significantly better than the same rating for BIIB (89). This means that REGN's stock grew significantly faster than VRTX’s and significantly faster than BIIB’s over the last 12 months.
VRTX's Profit vs Risk Rating (35) in the Biotechnology industry is somewhat better than the same rating for REGN (75) and is somewhat better than the same rating for BIIB (100). This means that VRTX's stock grew somewhat faster than REGN’s and somewhat faster than BIIB’s over the last 12 months.
VRTX's SMR Rating (40) in the Biotechnology industry is in the same range as REGN (54) and is somewhat better than the same rating for BIIB (78). This means that VRTX's stock grew similarly to REGN’s and somewhat faster than BIIB’s over the last 12 months.
REGN's Price Growth Rating (47) in the Biotechnology industry is in the same range as BIIB (47) and is in the same range as VRTX (60). This means that REGN's stock grew similarly to BIIB’s and similarly to VRTX’s over the last 12 months.
BIIB's P/E Growth Rating (14) in the Biotechnology industry is in the same range as REGN (40) and is somewhat better than the same rating for VRTX (53). This means that BIIB's stock grew similarly to REGN’s and somewhat faster than VRTX’s over the last 12 months.
| BIIB | REGN | VRTX | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 65% | 2 days ago 75% | 2 days ago 64% |
| Momentum ODDS (%) | 2 days ago 57% | 2 days ago 52% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 49% | 2 days ago 62% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 66% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 60% | 2 days ago 36% |
| Advances ODDS (%) | 4 days ago 57% | 18 days ago 64% | 5 days ago 63% |
| Declines ODDS (%) | 9 days ago 72% | 3 days ago 51% | 3 days ago 43% |
| BollingerBands ODDS (%) | 2 days ago 46% | 2 days ago 49% | N/A |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 70% | 2 days ago 30% |
Advertisement